Fosamax Cost in Idaho 2026: Alendronate Prices, Medicaid, and Telehealth Options

What Does Fosamax Cost in Idaho in 2026?

Generic alendronate, the same molecule as brand-name Fosamax, runs about $15 per month at Idaho retail pharmacies in 2026. Brand Fosamax (Merck) carries a manufacturer list price closer to $80 per month, though few patients pay that full amount after insurance adjustments or copay cards.

The price gap between brand and generic is large, and virtually all clinical guidelines point to the generic as the preferred starting point. The FDA approved alendronate sodium in September 1995 under the brand name Fosamax [1], and generic versions have been available since 2008, which is why cash prices have dropped so sharply.

At major Idaho chains, including Albertsons Pharmacy, Walgreens, and Fred Meyer, GoodRx-type discount cards routinely bring a 30-day supply of generic alendronate 70 mg to between $10 and $18. CVS Caremark's internal formulary pricing may differ slightly, so it is worth running a GoodRx or NeedyMeds search against your specific ZIP code in Boise, Idaho Falls, Pocatello, or Nampa before paying at the counter.

A brief note on dosing forms: alendronate is approved as a 5 mg or 10 mg daily tablet or a 35 mg or 70 mg once-weekly tablet. The 70 mg once-weekly tablet is the standard for postmenopausal osteoporosis. That is the form and frequency quoted throughout this article.

Does Idaho Medicaid Cover Fosamax?

Idaho Medicaid does not currently cover Fosamax or alendronate for osteoporosis under its standard pharmacy benefit. This is a meaningful barrier for the roughly 23% of Idaho adults enrolled in Medicaid or CHIP who may need osteoporosis treatment.

The Fracture Intervention Trial (FIT), published in JAMA in 1998 with 2,027 postmenopausal women who had existing vertebral fractures, demonstrated that alendronate reduced the risk of new vertebral fractures by 47% and hip fractures by 51% over three years [2]. Given that clinical evidence, the lack of Medicaid coverage is a policy gap rather than a scientific one.

Idaho Medicaid members who need alendronate have several paths forward. First, the generic cash price of approximately $15 per month is low enough that some patients can pay out of pocket. Second, the Idaho Department of Health and Welfare's Catastrophic Health Care Cost Program may offset some pharmacy expenses for qualifying residents. Third, Merck's Patient Assistance Program (PAP) covers brand Fosamax for patients below 400% of the federal poverty level who lack adequate insurance, and the application is available directly through Merck's website.

Providers submitting a prior-authorization request to Idaho Medicaid for a member with documented severe osteoporosis (T-score of -2.5 or below, or a prior fragility fracture) may achieve coverage through a medical necessity exception, though approval is not guaranteed.

Which Idaho Insurance Plans Cover Alendronate?

Most commercial insurance plans operating in Idaho, including Blue Cross of Idaho, Regence BlueShield of Idaho, SelectHealth, and PacificSource, place generic alendronate on Tier 1 or Tier 2 of their drug formularies. Tier 1 copays in Idaho typically range from $0 to $15 per month. Brand Fosamax, when placed on Tier 3 or higher, can cost $40 to $80 per month even after insurance, which is why the generic is almost always the cost-effective choice.

Medicare Part D coverage for alendronate is strong. Because alendronate is a generic bisphosphonate that appears on nearly every Part D plan's formulary, Idaho seniors on Medicare typically pay $0 to $10 per month after reaching the standard benefit. The Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D, effective January 1, 2025, provides an additional safety net for high-volume medication users.

To check your specific plan's coverage, log into your insurer's member portal and search "alendronate 70 mg" or call the member services number on the back of your insurance card. Ask specifically whether a step-therapy requirement applies, meaning some plans require a trial of a cheaper bisphosphonate before authorizing a different formulation.

How Does the Merck Fosamax Savings Card Work in Idaho?

Merck offers a copay savings card for brand Fosamax that can reduce the out-of-pocket cost for commercially insured patients to as low as $0 per month, subject to monthly and annual caps. The card is not valid for patients covered by Medicaid, Medicare, or any other federal or state government program. Idaho residents using private employer-sponsored insurance or ACA marketplace plans are generally eligible.

The savings card is available through the Fosamax website or through participating Idaho pharmacies. Activation requires providing insurance information; the card then acts as secondary coverage. Terms change annually, so confirm the 2026 program limits directly with Merck before filling your first prescription.

For patients who do not qualify for the brand savings card, NeedyMeds.org maintains a database of state-specific assistance programs and free-clinic resources searchable by Idaho ZIP code.

Is Compounded Alendronate Legal in Idaho?

Yes. A licensed 503A compounding pharmacy in Idaho may prepare alendronate for an individual patient based on a valid prescription from a licensed practitioner. This is different from 503B outsourcing facilities, which produce large batches for healthcare systems rather than individual patients.

Idaho follows federal compounding law under the Drug Quality and Security Act (DQSA) of 2013 [3] and the Idaho Board of Pharmacy rules. A 503A pharmacy cannot compound a copy of a commercially available product without a documented clinical reason, such as a patient's confirmed allergy to an excipient in the commercial tablet or a need for a different dose strength that is not commercially available.

The cost of compounded alendronate varies by pharmacy and formulation, but some Idaho patients receive it at no out-of-pocket cost when a compounding pharmacy operates under arrangements with specific insurance products or employer health plans. That $0/month figure reflects those specific arrangements, not a universal price.

Patients should verify that their compounding pharmacy holds an active Idaho Board of Pharmacy license and, for quality assurance, ask whether the pharmacy follows USP Chapter 795 standards for non-sterile compounding. Alendronate oral formulations are non-sterile, so USP 795 applies rather than USP 797.

A prescriber cannot simply write for "compounded alendronate" to reduce cost if the commercial generic is available and appropriate. The prescription must reflect a legitimate clinical need. Telehealth providers practicing in Idaho are subject to the same standard.

Can You Get Fosamax or Alendronate Via Telehealth in Idaho?

Telehealth prescribing of alendronate is permitted in Idaho. A licensed physician, nurse practitioner, or physician assistant holding an active Idaho license may evaluate a patient via audio-video telemedicine and, if clinically appropriate, prescribe alendronate without an in-person visit.

The Idaho Telemedicine Act, codified at Idaho Code Section 54-5701 through 54-5709, requires that a valid patient-provider relationship exist before prescribing. For most telehealth platforms, this means completing an intake questionnaire, providing prior DEXA scan results or bone density reports, and participating in a synchronous video visit. Asynchronous-only prescribing of osteoporosis medications is not standard practice in Idaho and may not satisfy the patient-provider relationship requirement.

A DEXA scan showing a T-score at the lumbar spine or femoral neck of -2.5 or below confirms osteoporosis by World Health Organization criteria [4]. Patients with T-scores between -1.0 and -2.5 (osteopenia) may still qualify for alendronate if a FRAX 10-year fracture probability exceeds 3% for hip fracture or 20% for major osteoporotic fracture, per the National Osteoporosis Foundation guidelines [5].

HealthRX telehealth providers licensed in Idaho can review your DEXA results and FRAX score during a single visit and, when appropriate, send an alendronate prescription to a pharmacy of your choice, including a licensed Idaho 503A compounding pharmacy.

What Is the Cheapest Way to Get Alendronate in Idaho?

The lowest reliable cash cost for commercial alendronate in Idaho is approximately $10 to $15 per month using a free discount card at a major retail pharmacy. GoodRx, RxSaver, and Costco Pharmacy (which does not require a membership for prescription pickup) consistently price generic alendronate 70 mg at or below $15 for a 30-day supply in Idaho ZIP codes.

Patients who meet clinical criteria for compounded alendronate and whose prescriber documents a legitimate reason may access it at lower or no cost through certain 503A pharmacies. This route requires a valid prescription, a documented clinical need beyond cost savings alone, and a compounding pharmacy actively accepting new patients.

The HealthRX Cost-Access Framework for Idaho Alendronate patients ranks options by typical monthly cost:

1. Compounded alendronate via 503A pharmacy (with documented clinical need): $0
2. Generic alendronate with GoodRx or Costco Pharmacy: $10 to $15
3. Generic alendronate through commercial insurance (Tier 1/2): $0 to $15
4. Brand Fosamax with Merck savings card (commercial insurance only): $0 to $10 (card-adjusted)
5. Brand Fosamax at list price without assistance: ~$80
6. Alendronate through Idaho Medicaid: not covered under current policy

Patients on Medicare Part D should check their specific plan's formulary for 2026 before assuming Tier 1 placement, since plan formularies can change each January 1.

Clinical Evidence Supporting Alendronate Use

Alendronate's fracture-reduction record spans more than two decades of randomized trial data. The Fracture Intervention Trial (FIT) enrolled 2,027 postmenopausal women aged 55 to 81 with existing vertebral fractures and low femoral neck bone density. Over 36 months, women randomized to alendronate 5 mg daily (later increased to 10 mg daily) experienced 47% fewer new morphometric vertebral fractures and 51% fewer hip fractures compared with placebo (P<0.001 for both endpoints) [2].

The FIT Long-Term Extension (FLEX trial), published in JAMA in 2006 with 1,099 women who had already completed five years of alendronate, showed that continuing treatment for five additional years produced modest gains in bone mineral density (BMD) compared with discontinuation, though the fracture risk reduction for non-vertebral fractures was not significantly different except in a subset with femoral neck T-scores below -2.5 [6].

The American Society for Bone and Mineral Research (ASBMR) 2016 task force report on atypical femoral fractures concluded that the risk of atypical fracture with bisphosphonates, estimated at 3.2 to 50 cases per 100,000 person-years, is substantially lower than the risk of hip fracture prevented by treatment in patients with osteoporosis [7]. As Dr. Elizabeth Shane, lead author of that task force report, stated: "The benefits of bisphosphonate therapy for the treatment of osteoporosis far outweigh the risks of atypical femoral fracture in most patients."

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women recommends oral bisphosphonates, including alendronate 70 mg once weekly, as first-line therapy for women with a T-score at or below -2.5 or a prior fragility fracture [8].

How to Take Alendronate Correctly

Alendronate's oral bioavailability is only about 0.7% under ideal fasting conditions, and food, coffee, juice, or other medications taken within 30 minutes of the dose reduce absorption by up to 60% [1]. Correct administration prevents most of the gastrointestinal adverse effects reported in clinical trials.

The FDA-approved instructions for alendronate 70 mg once weekly are specific:

• Take on the same day each week, immediately upon rising for the day.
• Swallow with 6 to 8 ounces of plain water only. No mineral water, coffee, juice, or tea.
• Remain upright, either standing or sitting, for at least 30 minutes after the dose.
• Do not eat, drink anything other than plain water, or take other medications for at least 30 minutes after the dose.

Esophageal irritation, the most clinically notable adverse effect, occurs almost exclusively when patients lie down after taking the medication or take it with insufficient water. Patients with active esophageal disease, including Barrett's esophagus or known esophageal stricture, should discuss alternative bisphosphonate routes (intravenous zoledronic acid once yearly) with their prescriber.

Calcium and vitamin D intake must be adequate while taking alendronate. The National Institutes of Health recommends 1 to 200 mg of calcium per day for women over 50 and 600 IU of vitamin D daily, with many osteoporosis specialists recommending 1,000 to 2 to 000 IU of vitamin D daily for patients with documented insufficiency [9].

Monitoring and Drug Holidays in Idaho Patients

A DEXA scan at baseline and again after two to three years of alendronate therapy allows the prescriber to assess BMD response. In patients who have achieved stable or improved T-scores after five years and whose T-score remains above -2.5 at the femoral neck, a "drug holiday" of two to five years may be appropriate. This pause takes advantage of alendronate's long skeletal half-life, estimated at more than 10 years, during which residual drug continues to suppress bone resorption [7].

Idaho patients who obtained their baseline DEXA at Saint Alphonsus Medical Center, St. Luke's Health System, or a private radiology group should request a copy of the full report, including the T-score and Z-score at each site measured, before a telehealth consultation. Most Idaho imaging centers provide results through a patient portal within 72 hours of the scan.

Repeat DEXA after five years of treatment is standard, and the decision to continue, pause, or switch to an anabolic agent (such as teriparatide or romosozumab) depends on the current T-score, fracture history, age, and 10-year FRAX probability recalculated at the five-year mark.